BioNTech to Host Innovation Series R&D Day on November 11, 2025

Rhea-AI Summary

BioNTech (Nasdaq: BNTX) will host an Innovation Series R&D Day on Tuesday, November 11, 2025 at 09:00 a.m. EST (3:00 p.m. CET) in New York City. Company leadership will provide an overview of BioNTech’s strategy and clinical progress across its pipeline.

Investors, analysts and the public can join the event online via webcast; a replay will be available shortly after the event and archived on the company website for one year. Presentation slides will be posted on the Investor Relations “Events & Presentations” page at www.BioNTech.com.

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S.

On the day, members of BioNTech’s leadership team will provide an overview of the Company’s strategy and clinical progress across its pipeline.

Investors, analysts and the interested public are invited to join the event online via this link.

A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company’s website for one year following the call. The public may also access the presentation slides via the “Events & Presentations” page of the Investor Relations section of the Company’s website at www.BioNTech.com. 

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit  www.BioNTech.com.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de

FAQ

When is BioNTech's R&D Day for BNTX and what time does it start?

BioNTech's R&D Day is on November 11, 2025, starting at 09:00 a.m. EST (3:00 p.m. CET).

How can investors watch the BioNTech (BNTX) Innovation Series R&D Day webcast?

Investors can join the live webcast via the company’s online link and view a replay archived on the website.

Will BioNTech (BNTX) make presentation slides available after the R&D Day?

Yes. Presentation slides will be posted on the Investor Relations “Events & Presentations” page at www.BioNTech.com.

How long will the BioNTech (BNTX) R&D Day webcast replay be available?

The replay will be archived on the company website and available for one year following the event.

What topics will BioNTech leadership cover at the November 11, 2025 R&D Day?

Leadership will provide an overview of the company’s strategy and clinical progress across its pipeline.

Where is BioNTech hosting the November 11, 2025 R&D Day?

The event will be held in New York City, U.S., with online access available to the public.